Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sarbanes-Oxley exemption

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed and the Medical Device Manufacturer's Association join a coalition of technology associations in an April 3 letter urging the Securities and Exchange Commission to adopt a draft guidance that would ease external auditing requirements for public companies with annual fiscal revenues under $250 mil. The letter states that "this approach will begin to address the disproportionate cost burdens of section 404 requirements that continue to hamper smaller companies' ability to invest in research and development, to gain access to public capital markets, and to remain competitive." Since it was enacted in 2002, the Sarbanes-Oxley Act has required all public companies to pay to have their internal controls checked by an external auditor (1"The Gray Sheet" Dec. 19, 2005, p. 11)...

You may also be interested in...

Panel Says Small Public Firms Should Be Exempt From External Auditing Law

A Securities & Exchange Commission committee voiced approval for changes to the Sarbanes-Oxley Act that could save small device firms millions of dollars spent to comply with external auditing requirements

QUOTED. 23 October. Dan Buehner.

Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.

Gilead’s Veklury Approval Shows US FDA’s Existing Regulatory Tools Are Up To The COVID-19 Challenge

The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts